AI Summary

Mattias Hammarström’s thesis examined whether lower doses of tamoxifen and its active metabolite endoxifen could serve as preventive medication for breast cancer while reducing side effects. The study found that both lower-dose tamoxifen and a low dose of endoxifen may provide a better balance between biological effects on breast tissue and adverse reactions. These findings suggest that individualized dosing could improve the risk–benefit profile for healthy women considering preventive therapy. Breast cancer remains the most common cancer among women worldwide, and prevention continues to be a key research focus.

AI summaries can be wrong sometimes—always verify important details using the source article.